eViralHepatitis Review
Latest Episodes
HBV: Addressing Current Gaps in Diagnosis and Linkage to Care
Volume 5, Issue 2. Our guests authors are Mindie Nguyen, MD, MAS, from Associate Professor of Medicine at Stanford University, and Dr. Iris Liou, MD of the University of Washington. Take our post-test to claim CME credits: Physician post-test Nurse pos...
Extrahepatic Manifestations of Hepatitis C: Screening and Management
Volume 4, Issue 14. Drs Jordan Feld, MD, MPH and Joel Emery, HBSc, MD cover the important topic of Extrahepatic Manifestations of Hepatitis C: Screening and Management in the format of case-study scenarios for the clinical practice.
Volume 4, Issue 14
Extrahepatic Manifestations of Hepatitis C: Screening and Management
Emerging Therapeutic Approaches for Chronic Hepatitis B
Volume 4, Issue 12. Our guest author is Chloe Thio, MD, Professor of Medicine, Divison of Infectious Diseases at the Johns Hopkins University School of Medicine. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a com...
New Approaches to the Diagnosis and Management of Chronic HBV Infection
Volume 4, Issue 10. Drs Kenneth Sherman, MD, PhD and Nadeem Anwar, MD cover the important topic of New Approaches to the Diagnosis and Management of Chronic HBV Infection in the format of case-study scenarios for the clinical practice.
Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study
Volume 4, Issue 8, Part 3. Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infecte...
Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES)
Volume 4, Issue 8, Part 2. Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected wit...
High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals
Volume 4, Issue 8, Part 1. Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treat...